

# PATENT COOPERATION TREATY

TRANSLATION

From the  
INTERNATIONAL SEARCHING AUTHORITY

## PCT

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

To:

Date of mailing  
(day/month/year)

Applicant's or agent's file reference

**MP5112WO**

**FOR FURTHER ACTION**

See paragraph 2 below

International application No.

**PCT/JP2005/001932**

International filing date (day/month/year)

**09.02.2005**

Priority date (day/month/year)

**09.02.2004**

International Patent Classification (IPC) or both national classification and IPC

Applicant

**MITSUBISHI PHARMA CORPORATION**

1. This opinion contains indications relating to the following items:

- |                                     |              |  |
|-------------------------------------|--------------|--|
| <input checked="" type="checkbox"/> | Box No. I    | Basis of the opinion   |
| <input type="checkbox"/>            | Box No. II   | Priority   |
| <input checked="" type="checkbox"/> | Box No. III  | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability   |
| <input type="checkbox"/>            | Box No. IV   | Lack of unity of invention   |
| <input checked="" type="checkbox"/> | Box No. V    | Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| <input type="checkbox"/>            | Box No. VI   | Certain documents cited  |
| <input type="checkbox"/>            | Box No. VII  | Certain defects in the international application   |
| <input type="checkbox"/>            | Box No. VIII | Certain observations on the international application  |

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/JP

Authorized officer

Facsimile No.

Telephone No.

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2005/001932

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.  
☐ This opinion has been established on the basis of a translation from the original language into the following language \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (under Rule 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
  - a. type of material  
☐ a sequence listing  
☐ table(s) related to the sequence listing
  - b. format of material  
☐ in written format  
☐ in computer readable form
  - c. time of filing/furnishing  
☐ contained in the international application as filed.  
☐ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority for the purposes of search.
3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2005/001932

Box No. III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application

☒ claims Nos. 17-32

because:

☒ the said international application, or the said claims Nos. 17-32  
relate to the following subject matter which does not require an international preliminary examination (*specify*):

The inventions of claims 17-32 concern a method of treatment of the human body by therapy, and no search thereof is required of the International Searching Authority.

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. \_\_\_\_\_  
are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. \_\_\_\_\_ are so inadequately supported  
by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. 17-32

☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form

☐ has not been furnished

☐ does not comply with the standard

the computer readable form

☐ has not been furnished

☐ does not comply with the standard

☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.

☐ See Supplemental Box for further details.

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No. **PCT/JP2005/001932**

Box No. V Reasoned statement under Rule 43bis 1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Claims

1-16

YES

NO

Inventive step (IS)

Claims

1-16

YES

NO

Industrial applicability (IA)

Claims

1-16

YES

NO

2. Citations and explanations:

Document 1: WO 02/34264 A1

Document 2: JP 2003-81830 A

Document 3: JP 2003-83977 A

Documents 1, 2, and 3 describe that the compound of claim 1 is effective as a drug for the treatment of amyotrophic lateral sclerosis (ALS), and that it delays the progression of diseases such as ALS, and mitigates the symptoms thereof. The invention of claim 1 is a drug to be used for the treatment of ALS or the symptoms caused by ALS and/or inhibit the progression thereof having the specified compound as an active ingredient, and it concerns a drug wherein a specific washout period during the period of treatment and/or inhibition of progression. However, when we compare the invention of claim 1 with the inventions described in documents 1, 2, and 3, all involve the same drug to be used as a treatment for ALS, and are otherwise indistinguishable. Documents 1, 2, and 3 do not specifically describe the "fact that a washout period is established" in the invention of claim 1. However, this authority finds that establishing a washout period concerns the method of using a drug, and even though claim 1 states that this kind of washout period is established, this authority finds that as a drug the invention of claim 1 cannot be distinguished from the inventions described in documents 1, 2, and 3.

Document 1 does not specifically limit the route of administration as the method for using the drug described therein, and it states that the drug can be used orally or parenterally, that the dose can be selected as needed in accordance with various conditions such as the type of disease to be treated, the extent of progression and symptoms of the disease, the age and body weight of the patient, and the like, but generally a daily dose for adults will be 0.01 µg/kg to 10 mg/kg, and preferably 0.1 to 100 µg/kg administered as an injection or drip infusion. The method of administration can be selected as needed by persons skilled in the art, including establishing a washout period.